The UK Health Security Agency is urging students preparing to begin college or university this autumn to receive the meningitis B (MenB) vaccine ahead of freshers week. This recommendation comes amid concerns over meningitis B outbreaks earlier this year and aims to protect roughly one million young people eligible for this targeted vaccination campaign. However, so far only about 250,000 doses have been administered.
MenB is the leading cause of invasive meningococcal disease, including meningitis and septicaemia, among individuals under 25 years of age. Although cases are relatively rare, they tend to increase during late autumn. First-year university students are particularly vulnerable, estimated to be about seven times more likely to contract the disease than their peers not enrolled in higher education.
The UK introduced the MenB vaccine into its routine immunisation schedule for infants in 2015, offering protection to children born on or after May 1, 2015. However, immunity may wane over time, leaving teenagers and young adults susceptible to infection. The primary vaccine used in the UK, Bexsero, is effective against most but not all MenB strains, with an estimated efficacy of roughly 80 percent. Since its introduction, there has been a 75 percent reduction in serious MenB infections among the vaccinated age groups.
The current campaign, launched in July, focuses on teenagers and young adults, a demographic at highest risk alongside infants. It involves two doses administered at least four weeks apart, with the first dose available until the end of December 2026 and the second dose to be completed by March 2027. Eligible individuals include those born between September 1, 2007, and August 31, 2008—corresponding to year 13 in England and Wales and S6 or year 14 in Scotland and Northern Ireland—as well as anyone under 25 starting university or residential further education for the first time this academic year. Postgraduate students, returning undergraduates, and those who have completed a MenB vaccination course within the previous five years are excluded.
Side effects of the MenB vaccine are generally mild and temporary, similar to those experienced with other childhood immunisations, including general malaise, fever, and local swelling. For young infants, paracetamol is recommended following vaccination to alleviate these symptoms.
Looking ahead, the Joint Committee on Vaccination and Immunisation (JCVI) has advised that a single MenB dose be offered routinely to teenagers around 15 years old, with catch-up programmes for those who missed infant vaccination. These recommendations will require government approval before implementation.
It is important to note that the MenB vaccine is distinct from the MenACWY vaccine given to adolescents, which does not protect against meningitis B strains.
Health officials emphasize the importance of awareness alongside vaccination, as early recognition of symptoms can be critical. Meningitis and septicaemia can progress rapidly but often respond well to prompt treatment. Classic symptoms include high fever, vomiting, severe headache, sensitivity to light, and a distinctive reddish-purple rash that does not fade under pressure. Additional warning signs may include confusion, drowsiness, seizures, limb pain, blotchy skin, and cold extremities.
Students and caregivers are encouraged to remain vigilant and seek medical help immediately if meningitis is suspected, as delays in diagnosis can have severe consequences. Information on symptoms and vaccination availability is accessible on NHS platforms and health agency websites.